Is Novartis a Cash King?
As an investor, it pays to follow the cash. If you figure out how a company moves its money, you might eventually find some of that cash flowing into your pockets.
In this series, we'll highlight four big dogs in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting cash back in your pocket. After all, a company can pay dividends and buy back stock only after it's actually received cash -- not just when it books those accounting figments known as "profits."
The cash king margin
Looking at a company's cash flow statement can help you determine whether its free cash flow actually backs up its reported profit. Companies that can create 10% or more free cash flow from their revenue can be powerful compounding machines for your portfolio.
To find the cash king margin, divide the free cash flow from the cash flow statement by sales:
Cash king margin = Free cash flow / sales
Let's take McDonald's as an example. In the four quarters ending in June, the restaurateur generated $6.87 billion in operating cash flow. It invested about $2.44 billion in property, plant, and equipment. To calculate free cash flow, subtract McDonald's investment ($2.44 billion) from its operating cash flow ($6.87 billion). That leaves us with $4.43 billion in free cash flow, which the company can save for future expenditures or distribute to shareholders.
Taking McDonald's sales of $25.5 billion over the same period, we can figure that the company has a cash king margin of about 17% -- a nice high number. In other words, for every dollar of sales, McDonald's produces $0.17 in free cash.
Ideally, we'd like to see the cash king margin top 10%. The best blue chips can notch numbers greater than 20%, making them true cash dynamos. But some businesses, including many types of retailing, just can't sustain such margins.
We're also looking for companies that can consistently increase their margins over time, which indicates that their competitive position is improving. Erratic swings in margins could signal a deteriorating business, or perhaps some financial skullduggery; you'll have to dig deeper to discover the reason.
Today, let's look at Novartis (NYS: NVS) and three of its peers:
Cash King Margin (TTM)
1 Year Ago
3 Years Ago
5 Years Ago
|Sanofi (NYS: SNY)||24.0%||20.8%||19.5%||15.9%|
|Bristol-Myers Squibb (NYS: BMY)||20.6%||19.4%||11.8%||6.4%|
|Abbott Laboratories (NYS: ABT)||21.8%||23.1%||14.9%||19.4%|
Source: Capital IQ, a division of Standard & Poor's. TTM = trailing 12 months.
The numbers here are what you would expect from a patent-based business that lets companies exploit their intellectual property. All of the listed companies offer cash king margins far higher than our 10% threshold. Novartis has the lowest margins of the listed companies, and they have declined consistently over the past three years. Sanofi has the highest margins, and has shown fairly consistently growth over the past five years, as has Bristol-Myers Squibb. Abbott's margins have fluctuated a great deal over the past five years. Compare these returns to the blue chips of software and biotech to get some context.
The cash king margin can help you find highly profitable businesses, but it should only be the start of your search. The ratio does have its limits, especially for fast-growing small businesses. Many such companies reinvest all of their cash flow into growing the business, leaving them little or no free cash -- but that doesn't necessarily make them poor investments. You'll need to look closer to determine exactly how a company is using its cash.
Still, if you can cut through the earnings headlines to follow the cash instead, you might be on the path toward seriously great investments.
Want to read more about Novartis? Add it to My Watchlist, which will find all of our Foolish analysis on this stock.
- Add Novartis to My Watchlist.
- Add Sanofi to My Watchlist.
- Add Bristol-Myers Squibb to My Watchlist.
- Add Abbott Laboratories to My Watchlist.
At the time this article was published Jim Royal owns shares of McDonald's. The Motley Fool owns shares of Abbott Laboratories.Motley Fool newsletter serviceshave recommended buying shares of Abbott Laboratories, Novartis, and McDonald's. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.